Search Results

Analog Devices, Inc. (Nasdaq: ADI ) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the commercial launch of the Sensinel ™ Cardiopulmonary Management (CPM) System.

EVONETIX LTD, the company developing semiconductor scale technology to improve access to gene synthesis, announces the signing of a joint development agreement and commercial supply agreement with Analog Devices, Inc., a global semiconductor leader.

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide

MIRA Pharmaceuticals, Inc. announced it is in advanced discussions with Memorial Sloan Kettering Cancer Center (MSK) to initiate a preclinical study evaluating MIRA’s novel oral ketamine analog, Ketamir-2, for the treatment of cancer-related pain and depression.

MIRA Pharmaceuticals, Inc. announced that it has advanced new preclinical studies using Ketamir-2, its differentiated oral ketamine analog, towards clinical development for the treatment of severe post-traumatic stress disorder (PTSD) and other leading mental health disorders and neuropathic pain indications.

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, today announced positive preclinical study results highlighting the potential efficacy and safety profile of Ketamir-2, MIRA’s novel oral ketamine analog designed to treat depression and treatment-resistant depression (TRD).

Sciwind Biosciences Co., Ltd. announced that the company will present positive results from a Phase 3 clinical study of injectable ecnoglutide in T2DM patients and from a Phase 1 study for oral ecnoglutide in healthy and healthy obese participants, as well as preclinical data for novel amylin analog programs, at the American Diabetes Association 84th Annual Conference.

Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality weight loss with a cleaner tolerability profile.

Gilgamesh Pharmaceuticals today announced that it has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, its novel, cardiac-safe ibogaine analog for the treatment of substance use disorders.